RWE and HTA – a snapshot of recent developments with Sreeram Ramagopalan: February–March 2022

11 May 2022

Written by Sreeram Ramagopalan (F. Hoffmann-La Roche)

Guest columns Health technology assessment Industry Updates Interviews Journal articles Real-world evidence

Read highlights from the latest instalment of Sreeram Ramagopalan’s (F. Hoffman La Roche, Basel, Switzerland) industry news round-up, which discusses some of the latest developments regarding real-world evidence (RWE) in the context of health technology assessment (HTA) and is published bi-monthly in our partner journal, the Journal of Comparative Effectiveness Research. Read the full update for February–March 2022 in the Journal of Comparative Effectiveness Research here >>> What happened over these months that you were expecting? It was good to see the publication around target trial emulation (TTE) and its potential utilization in HTA. The paper introduces the concept of...